Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Large granular lymphocyte leukemia.

Lubomir Sokol1, Thomas P Loughran

  • 1Department of Interdisciplinary Oncology, University of South Florida and H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.

The Oncologist
|March 22, 2006
PubMed
Summary

Large granular lymphocyte (LGL) leukemia encompasses T-cell and NK-cell disorders, varying from indolent to aggressive. While T-cell LGL leukemia often has a good prognosis, aggressive NK-cell LGL leukemia is rapidly progressive and difficult to treat.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Revisiting the Origins of Cutaneous T-Cell Lymphoma: A Progenitor-Based Model.

Cancers·2026
Same author

Flow cytometric analysis of phenotypes and naïve/memory/effector T-cell subsets of T-cell large granular lymphocytic leukemia.

Leukemia & lymphoma·2026
Same author

Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis.

Annals of the rheumatic diseases·2026
Same author

Real-time diagnosis of adult T-cell leukemia/lymphoma using HBZ RNA in situ hybridization.

American journal of clinical pathology·2026
Same author

Acid ceramidase inhibition enhances BCL-2 targeting in venetoclax-resistant acute myeloid leukemia.

Blood neoplasia·2026
Same author

Pharmacological blockade of rho kinase enhances venetoclax responses in translational models of acute myeloid leukemia.

Haematologica·2026

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Clonal disorders of large granular lymphocytes (LGLs) are lymphoproliferative diseases.
  • These disorders originate from either mature T cells (CD3+) or natural killer (NK) cells (CD3-).
  • LGL leukemia subtypes include T-cell and NK-cell LGL leukemia, presenting as indolent or aggressive conditions.

Purpose of the Study:

  • To review the clinical spectrum, prognosis, and treatment of T-cell and NK-cell large granular lymphocyte leukemia.
  • To differentiate between indolent and aggressive forms of LGL leukemia.
  • To highlight the challenges in diagnosing and treating NK-cell LGL leukemia.

Main Methods:

  • Literature review of large granular lymphocyte disorders.
  • Analysis of clinical presentations and outcomes for T-cell and NK-cell LGL leukemia.

Related Experiment Videos

  • Discussion of therapeutic approaches including immunosuppressive agents and chemotherapy.

    • Main Results:

    • T-cell LGL leukemia is typically indolent with >10 years median survival, responsive to immunosuppressive therapy in >50% of cases.
    • Aggressive T-cell LGL leukemia (CD3+ CD56+) has a poor prognosis.
    • Aggressive NK-cell LGL leukemia is EBV-associated, rapidly progressive, refractory to chemotherapy, with a median survival of 2 months.
    • Chronic NK-cell leukemia/lymphocytosis is rare, EBV-negative, indolent, with uncertain malignant origin.

    Conclusions:

    • Large granular lymphocyte leukemia presents diverse clinical courses and prognoses based on cell origin (T-cell vs. NK-cell) and specific subtype.
    • Immunosuppressive therapy is effective for indolent T-cell LGL leukemia, but aggressive variants and NK-cell LGL leukemia pose significant treatment challenges.
    • Accurate diagnosis and classification are crucial for managing LGL leukemia subtypes effectively.